For all press and media enquiries please contact mediarelations@chiesi.com
Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the maintenance treatment in adult patients with moderate to severe chronic obstructive…
Chiesi is the first pharmaceutical company to have demonstrated with randomized clinical trials, two of which published in The Lancet 1,2, the efficacy of the triple extrafine combination to prevent exacerbations, improve symptoms and quality of life. Trimbow is the first fixed triple combination as…
Chiesi Farmaceutici Spa (“Chiesi”) acknowledges that uniQure biopharma B.V (uniQure), have taken the decision to withdraw the ongoing application for the Marketing Authorization Renewal of Glybera, for which Chiesi holds commercialization rights for Europe and other selected countries. This request…
Chiesi Group closes 2016 with a turnover of € 1.571 million, up 7.0% on 2015 (+9.6% at a constant exchange rate). The international footprint of the Group continues to grow: 83% of turnover comes from the non-Italian market. Significant growth in the European affiliates, which have now reached a…
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study. TRINITY is the first study to demonstrate the superiority of triple therapy with a fixed dose combination of an inhaled…
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps Chiesi Farmaceutici welcomes the recently published GOLD report but identifies three key elements in the treatment recommendations, which deserve thorough evaluation and further revision: Limited evidence base Misalignment with approved…
Parma, Italy — November 21, 2016 — Chiesi Farmaceutici Spa (“Chiesi”), announced today that it has signed a definitive agreement for the acquisition of Atopix Therapeutics Limited, a UK clinical stage biotechnology company developing novel treatments for asthma. Under the terms of the agreement,…
Tuesday, November 8 -- The Italian Prime Minister Matteo Renzi, has today visited Chiesi Farmaceutici at the Research Center in Parma. The Prime Minister scheduled a meeting with Ugo di Francesco, Group CEO, Paolo Chiesi, Vice President, Alessandro Chiesi, Region Europe Director and Andrea Chiesi,…
Chiesi Farmaceutici SpA (Chiesi) announces today the submission to the European Medicines Agency (EMA) of the marketing authorisation application for the first ICS/LABA/LAMA triple combination. The product is indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and is…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
